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Abstract 
Kainate induces a marked expression of cyclooxygenase-2 after its systemic administration. 
Because cyclooxygenase-2 activity is associated to the production of reactive oxygen species, 
we investigated the effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on kainate-
induced in vivo oxidative damage in the rat hippocampus. A clinically relevant dose of 
nimesulide (6 mg/kg, i.p.) was administered 3 times following kainate application (9 mg/kg, i.p.). 
After 24 h of kainate administration, the drastic decrease in hippocampal glutathione content and 
the significant increase in lipid peroxidation were attenuated in nimesulide-treated rats, 
suggesting that the induction of cyclooxygenase-2 is involved in kainate-mediated free radicals 
formation. 
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1. INTRODUCTION 
 
Kainate, a pyrrolidine excitotoxin isolated from the seaweed Digenea simplex, is a potent 
neuroexcitatory drug, which after intracerebral or systemic injection leads to generalized limbic 
seizures in rats (Ben Ari, 1985). Kainate-induced seizures are accompanied by severe neuronal 
damage predominantly in the hippocampus and amygdala/piriform cortex (Heggli and Malthe-
Sörenssen, 1982). The pattern of damage induced by systemically administered kainate 
approximates to that seen following repeated temporal lobe seizures (Ben Ari, 1985) and 
cerebral ischemia-reperfusion (Dykens et al., 1987). Therefore, kainate provides a valuable tool 
with which to model some features of ischemic damage and of the injury induced by repeated 
epileptic seizures (Sperk et al., 1985).   
 
Current models of kainate toxicity support the hypothesis that the main cause of neurotoxicity is 
the activation of presynaptic kainate receptors and the release of endogenous glutamate 
(Ferkany et al., 1982). The overstimulation of glutamate receptors has been implicated in the 
mediation of injury caused by neurotoxins and ischemia-related insults (Choi and Rothman, 
1990). Further, kainate is also thought to mediate damage partly through an indirect mechanism, 
which may involve the overproduction of reactive oxygen species. The generation of free 
radicals appears to be pivotal in kainate neurotoxicity (Cheng and Sun, 1994; Carriedo et al., 
1998). 
 
It was recently found that kainate induces a marked expression of cerebral cyclooxygenase-2 
mRNA and protein following its systemic administration (Hashimoto et al., 1998; Sandhya et al., 
1998; Sanz et al., 1997), but the link between kainate-mediated cyclooxygenase-2 induction and 
free radicals formation has not been clearly defined. In order to investigate the possibility that the 
induction of cyclooxygenase-2 is involved in kainate neurotoxicity, we examined the effects of 
nimesulide, a selective cyclooxygenase-2 inhibitor, on kainate-induced in vivo oxidative damage 
in the rat hippocampus. 
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2. MATERIALS AND METHODS 
 
2.1. Drugs  
Kainate was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Nimesulide was kindly 
provided by Gautier-Bagó Laboratories (Buenos Aires, Argentina). The Bioxytech LPO-586 kit 
for lipid peroxidation was obtained from Oxis International (Portland, OR, USA). All other 
reagents were of the highest quality available. 
 
2.2. Animals 
Male S.D. rats (CENPALAB, Havana, Cuba) with a body weight of 200-240 g were used for the 
experiments. The animals were housed in groups of 4 per cage in a room with controlled 12:12 
light/dark cycle and ad libitum food and water. 
 
2.3. Experimental design 
Four groups of rats (n=8 each) were prepared: (1) Kainate (9 mg/kg, i.p., in saline); (2) 
nimesulide (dissolved in polyvinylpyrrolidone (PVP) in the relation 1:4) was administered (6 
mg/kg, i.p.) immediately and after 1 and 2 h following kainate application (as in group 1); (3) 
saline + nimesulide and (4) saline + PVP (as the control group). 
 
2.4. Evaluation of behavioral changes 
The behavior of the animals was evaluated during 4 h after injection of kainate according to the 
following rating scale (Sperk et al., 1985): 0: normal, rare wet dog shakes, no convulsions; 1: 
intermediate number of wet dog shakes, rare focal convulsions affecting head and extremities, 
staring and intense immobility; 2: frequent wet dog shakes, frequent focal convulsions (no 
rearing or salivation); 3: frequent wet dog shakes, progression to more severe convulsions with 
rearing and salivation (but without falling over); 4: continuous generalized seizures (rearing, 
falling over), salivation; 5: generalized tonic-clonic seizures, death within 4 h in status 
epilepticus. 
 
2.5. Sample preparation 
After 24 h, animals were anesthetized with diethyl ether and perfused intracardially with ice-cold 
saline. Brains were quickly removed and frozen at -20°C until assay; the hippocampus was 
dissected on a cold stage before freezing. Hippocampi from treated rats were homogenized in 
20 mM Tris-HCl buffer (pH 7.4) and centrifuged for 10 min at 12 000 x g. The supernatant was 
collected and immediately tested for lipid peroxidation and glutathione content. 
 
2.6. Lipid peroxidation assay 
Lipid peroxidation was assessed by measuring the concentration of malonaldehyde and 4-
hydroxyalkenals using the Bioxytech LPO-586 kit. The assay was conducted according to the 
manufacturer’s instructions. 
 
2.7. Glutathione (GSH) assay 
Hippocampal glutathione content was measured spectrophotometrically in the deproteinized 
samples according to the procedure of Ellman (1959). 
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2.8. Protein assay 
Total protein concentration was determined using the Coomassie Blue method (Spector, 1978) 
with bovine serum albumin as standard. 
 
2.9. Statistical analysis 
Data are expressed as mean values ± SD (standard deviations). Results were analyzed by one-
way analysis of variance (ANOVA). If the F values were significant, the Students-Newman-Keuls 
post-hoc test was used to compare groups. Statistical significance was accepted for P<0.05 and 
P<0.01. 
 
 
3. RESULTS 
 
3.1. Behavior 
The most characteristic behavioral changes observed after i.p. injection of kainate  (9 mg/kg) 
were, in order of appearance, strong immobility, increased incidence of wet dog shakes and, 
initially, focal convulsions. Within 40-60 min after kainate administration the convulsive activity 
progressed to generalized limbic seizures. Although the intensity of these symptoms showed 
considerable inter-individual variation, the average symptom rating in both kainate-treated 
groups reached a value of 3. Nimesulide did not modify the kainate-induced behavioral changes. 
 
3.2. Effects of nimesulide on kainate-mediated oxidative damage 
After 24 h, the systemic administration of kainate (9 mg/kg, i.p.) produced a drastic decrease in 
hippocampal GSH levels (0.987 ± 0.06 μmol/g tissue) as compared to those in control group 
(1.316 ± 0.03 μmol/g tissue; P<0.01). Nimesulide (6 mg/kg, i.p., administered 3 times) partially 
prevented the dramatic decrease in GSH of kainate-challenged rats (1.182 ± 0.03 μmol/g tissue; 
P<0.05) as shown in Table 1. 
 
On the other hand, malonaldehyde and 4-hydroxyalkenals, as an index of lipid peroxidation, 
increased by 75% in kainate-treated group (6.45 ± 0.13 nmol/mg protein) as compared with 
control group (3.69 ± 0.24 nmol/mg protein; P<0.01). Kainate-mediated lipid peroxidation was 
attenuated in nimesulide-administered rats as shown in Fig. 1 (4.68 ± 0.09 nmol/mg protein; 
P<0.01). The administration of nimesulide without kainate did not alter neither GSH nor 
malonaldehyde and 4-hydroxyalkenals levels.  
 
 
4. DISCUSSION  
 
The ability of kainate to induce oxidative damage has been well documented in the literature 
(Cheng and Sun, 1994; Carriedo et al., 1998). It is generally accepted that overactivation of 
excitatory amino acid receptors triggers marked intracellular Ca2+ rises and consequent oxygen 
radical production. Multiple events may be elicited by kainate-induced cytosolic Ca2+ 
accumulation. Activation of calpains may convert xanthine dehydrogenase to xanthine oxidase 
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with the simultaneous formation of  free radicals. Further, Ca2+-dependent nitric oxide synthase 
activation may also contribute to kainate-mediated neuronal damage (Cheng and Sun, 1994). 
Moreover, the release of arachidonic acid following Ca2+-triggered phospholipase A2 activation 
plays an additional role in kainate-induced free radicals formation (Cheng and Sun, 1994). It has 
been demonstrated that inhibition of arachidonic acid metabolism protects against kainate-
induced seizures and neurotoxicity (Baran et al., 1994). 
 
Neuronal cyclooxygenase-2 expression is detected in certain regions of the rat brain, mainly the 
hippocampus and cortex under physiological conditions (Breder et al., 1995) and can be 
markedly induced under certain stimuli and insults, including seizures (Adams et al., 1996) and 
ischemia (Planas et al., 1995; Nogawa et al., 1997). Although the factors responsible for the 
cytotoxicity of cyclooxygenase-2 have not been clearly defined, it is likely that one of the 
mechanisms is related to production of reactive oxygen species, which are formed by the 
peroxidase step of the cyclooxygenase reaction. Cyclooxygenase-2 enzymatic activity can also 
mediate tissue damage by producing proinflammatory prostanoids (Seibert et al., 1995). 
 
As previously reported, systemic administration of kainate is able to increase prostaglandin 
formation and this event may be partially responsible for the tissue damage seen after kainate or 
the consequences of it (Baran et al., 1987). 
 
The effects of nimesulide have not previously been studied using the systemic kainate model of 
neurotoxicity. Our present results showed that nimesulide, a selective cyclooxygenase-2 
inhibitor, partially protected against kainate-induced oxidative damage. These results are 
consistent with previous reports, which provide strong evidence that cyclooxygenase-2 is 
implicated in excitotoxicity and neuronal death following brain insults such as ischemia-
reperfusion (Nogawa et al., 1997; Nakayama et al., 1998). 
 
In summary, the present study demonstrated that the administration of a clinically relevant dose 
of the cyclooxygenase-2 inhibitor nimesulide limited kainate-induced oxidative damage in the rat 
hippocampus. This finding may suggest that cyclooxygenase-2-derived reactive metabolites are 
involved in kainate excitotoxicity. On the other hand, nimesulide did not modify kainate-induced 
seizures. This may indicate that the effects of nimesulide are not sufficient to attenuate the 
kainate-mediated symptoms.  
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